Alkermes(US:ALKS) ZACKSยท2024-07-30 14:41Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2]. Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, helping investors identify securities likely to outperform the market in the short term [2][3]. - Stocks are rated from A to F, with A indicating the highest potential for outperformance [2]. Value Score - The Value Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [2]. Growth Score - The Growth Score assesses a company's future prospects by analyzing projected and historical earnings, sales, and cash flow [3]. Momentum Score - The Momentum Score evaluates stocks based on price trends and earnings outlook, helping investors capitalize on upward or downward price movements [3]. VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [4]. Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify stocks with high potential returns, with 1 (Strong Buy) stocks averaging a 25.41% annual return since 1988 [5][6]. - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment opportunities [6]. Company Spotlight: Alkermes (ALKS) - Alkermes plc is a biopharmaceutical company focused on developing treatments for central nervous system disorders, formed from a merger in 2011 [7]. - The company currently holds a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating solid performance potential [7][8]. - Alkermes has a Value Style Score of A, with a forward P/E ratio of 10.19, making it attractive to value investors [8]. - Recent upward revisions in earnings estimates suggest a consensus estimate of $2.74 per share for fiscal 2024, with an average earnings surprise of 5.8% [8].